Главная страницаLBank Stocks
UroGen Pharma Ltd
UroGen Pharma Ltd

UroGen Pharma Ltd (URGN)

24HВысокий$29.5024HНизкий$23.19
$28.11
+0.17%

Последнее обновление: 2026-11-17 10:58:51

Симуляция графика K-линий, фактические данные указаны на торговой странице

Ключевые данные

Открытие вчера
$24.00
Пред. закрытие
$28.11
Вчерашний диапазон
$23.19 - $29.50
Диапазон 52 нед.
$16.50 - $50.81
Объем торговли
3.736M
МС
$1.284B
P/E
--
EPS
$-1.31

Обзор компании

NASDAQ

UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel technology, the company enables targeted, sustained drug delivery, maximizing treatment efficacy while reducing systemic side effects. UroGen's strong clinical pipeline underscores its commitment to addressing substantial unmet medical needs in the oncology space, positioning the company as a potential leader in the urological oncology market and significantly improving patient outcomes.

СекторHEALTHCARE
ОтрасльBIOTECHNOLOGY
Штаб-квартира400 ALEXANDER PARK DRIVE, PRINCETON, NJ, UNITED STATES, 08540
СтранаUSA
Дата листинга2017-05-04
Конец финансового года2026-09-30
Акции в обращении49.048M
Код CIK1668243

Финансовые показатели

Индикатор2026-06-302026-03-312025-12-312025-09-30
Доход$72.456M$50.959M$37.837M$27.482M
Операционные расходы$6.572M$4.139M$3.289M$3.278M
Чистая прибыль-$14.351M-$23.574M-$26.364M-$33.347M
Чистая рентабельность-19.8%-46.3%-69.7%-121.3%
Прибыль на акцию$-0.28$-0.47$-0.54$-0.69
EBITDA-$3.757M-$19.003M-$22.188M-$25.768M
Эффективная налоговая ставка-64.5%16.8%1.0%3.1%

Часто задаваемые вопросы

URGN, or UroGen Pharma Ltd., operates in the healthcare sector and specializes in developing treatments for urological and oncological conditions. Its core business involves innovative drug delivery systems, particularly focused on non-surgical therapies for diseases affecting the urinary tract and bladder. The company utilizes proprietary technology to improve drug effectiveness and patient outcomes.
URGN operates in the healthcare sector within the biotechnology industry. It stands out by focusing on non-surgical remedies for urological diseases, unlike some competitors that emphasize surgical or invasive alternatives. Its proprietary drug-delivery technology gives URGN a unique market position, though competition remains strong from other biotech companies advancing treatments in similar therapeutic areas.
URGN has growth opportunities tied to expanding its market reach for urological disease treatments and receiving regulatory approvals for its pipeline products. The increased prevalence of conditions like non-muscle invasive bladder cancer also represents potential market demand. However, successful product launches and intellectual property protection will be crucial for revenue expansion.
URGN faces risks typical of biotech companies, including regulatory hurdles, high R&D costs, and dependence on clinical trial outcomes. There is additional risk from competition, which could impact market share for its products. As a relatively specialized company, it may also experience financial volatility based on the success or failure of its product pipeline.
URGN does not currently pay dividends, as is common among companies in the biotechnology industry. Instead, it reinvests capital into research and development to advance its drug pipeline and technology platform. Investors typically look for growth potential rather than dividend income when investing in companies like URGN.
URGN’s valuation is primarily influenced by its drug pipeline potential, clinical trial data, regulatory approvals, and market demand for its therapies. Other factors include intellectual property, financial health, and competitive positioning. Biotech companies often experience volatility in valuation due to these dynamic variables and reliance on early-stage innovations.
URGN's competitive advantages include its proprietary sustained-release drug delivery platforms and focus on non-surgical treatment areas, which differentiate it from competitors. Its innovative approach to treating urological diseases positions it favorably in a niche market. However, maintaining these advantages depends on successful clinical trials and protecting its intellectual property.
Investors should assess URGN’s research and development expenses, drug approval timelines, market potential for its products, and competition in its niche. Additionally, its access to funding, cash flow, and ability to secure partnerships or licensing deals are crucial factors for evaluating its financial sustainability and growth prospects.
Предупреждение о рисках
  1. 1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
  2. 2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
  3. 3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.